Combination of breast and lung cancer drugs ‘may overcome treatment resistance’

Combining two drugs for breast and lung cancer could potentially strip other tumours of their treatment resistance, a new study suggests.

Scientists discovered that when breast cancer drug palbociclib was combined with lung cancer drug crizotinib, the two-drug combination was significantly more effective against cancer cells in the laboratory than either drug used on its own.

Scientists at The Institute of Cancer Research, London (ICR), and UCL Cancer Institute discovered resistance to palbociclib is often driven by a protein which is targeted by crizotinib.

But the combined agents acted together to block cancer…
Read more posts United Kingdom or read the original


This content was imported with an automated system, without human intervention. You can report the removal of content by first reading our Legal Disclaimer